Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) has confirmed that cannabinoids CBG and CBC possess antitumor properties through a series of tests conducted at Israel based HTS (High-Throughput Screening Test) facility on human Gastrointestinal Cancer Cells. CBG (Cannabinoid Cannabigerol) has exhibited excellent antitumor activity on human bone cancer lines and stomach cancer when compared to the compound’s acid form.
The non-psychoactive cannabinoid – CBG is found in small quantities in raw cannabis. Cannabinoids, including CBC, CBN, CBD, and THC, are synthesized from CBG. It also exhibits anti-inflammatory properties. CBG may also work as an antibacterial agent.
CBC possess positive therapeutic qualities
Non-psychoactive cannabinoid – CBC is a naturally occurring Phyto-cannabinoid. It expects to promote analgesic, anti-inflammatory, antimicrobial, and neurogenesis activity. CBC offers a myriad of positive therapeutic qualities. It is available in smaller quantities in young cannabis plants.
Cannabics has used the HTS platform to find out the necrotic effects of several cannabinoids on the gastrointestinal cells of humans. CBG and CBC have shown impressive results in inducing a higher number of necrosis in the cancer cells when compared to other cannabinoids. Therefore, it strengthens previous results.
Reduces viability rate of cancer cells
The head (cannabidiol research) of Cannabics, Dr. Yaakov Waksman, said these results confirm that a correlation is likely between TPSA (Topological Polar Surface Area) of cannabinoids and its ability to promote antitumor activity. Therefore, it helps to mitigate the viability rates of cancer cells. The neutral cannabinoids – CBG and CBC possess TPSA value that allows the cannabinoids to penetrate the membrane of cancer cells.
Waksman said the scientific community is showing a lot of interest in CBG because of potential therapeutic properties. The research team of Cannabics has demonstrated the effects of purified cannabinoids in mitigating the tumors. These findings help the research team to verify the entourage effect of purified compounds against the botanical extracts. The company will conduct additional tests to support these findings soon.
Co-founder and Chief Technology Officer, Dr. Eyal Ballan, said gastrointestinal cancers are the chief leading cause of deaths across the world. He is pleased with the results obtained in the lab and will put more emphasis on exploring the differential antitumor properties of CBD.
Planet 13 Holdings Inc. (OTCMKTS:PLNHF) Signs Purchase Agreement To Acquire 45,000 Sq. ft. Facility In Nevada
Post Views: 108 Planet 13 Holdings Inc. (OTCMKTS:PLNHF) announced the signing of an asset purchase agreement subject to which it...
Indus Holdings Inc. (OTCMKTS:INDXF) Terminates Its Pending $20 million Acquisition Agreement Of W Vapes Assets
Post Views: 146 Indus Holdings Inc. (OTCMKTS:INDXF) announced termination of its impending acquisition of W Vapes assets that was announced...
1933 Industries Inc. (OTCMKTS:TGIFF) Introduces Pre-roll Joints And Smokable Cannabis Flower In Nevada
Post Views: 134 1933 Industries Inc. (OTCMKTS:TGIFF) announced addition of pre-joint rolls and high-quality smokable flowers to its growing consumer...
Cannabis Pharmaceuticals Inc. (OTCMKTS:CNBX) Initiates Expansion Of Its Cannabinoid Diagnostic Platform Tests In Europe
Post Views: 63 Cannabis Pharmaceuticals Inc. (OTCMKTS:CNBX) commenced expansion in the European markets to offer cancer patients tailored cannabinoid treatment...
Generex Biotechnology Corporation (OTCMKTS:GNBT) Submits Pre-IND For Ii-Key-SARS-CoV-2 Vaccine To The FDA
Post Views: 198 Generex Biotechnology Corporation (OTCMKTS:GNBT) submitted a Pre-IND update to the FDA outlining its proposed Phase I/II clinical...
cbdMD Inc. (NYSEAMERICAN:YCBD) Protecting Its CBD Technologies Through Patents and expands Partnership With Bellator MMA
Post Views: 310 cbdMD Inc. (NYSEAMERICAN:YCBD) announced an extension of the exclusive Official CBD marketing partnership with ViacomCBS’s wholly-owned subsidiary...